Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Director | August 27, 2026 | August 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date August 27, 2026 · Filed August 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,000 |
Reported balance
After 2026-08-27 transaction · row 1
1 source rowRow 1 · 2026-08-27 · Gift · Disposed 6,000 · Balance 39,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 04, 2014 Filed Nov 5, 2014 22:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,300 | $112.47 | $258,681.00 |
DisclosureSEC source: 0001209191-14-066728 · doc4.xml · nonDerivative · entry 5 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,910 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $112.47 (range $111.91 to $112.89). Read SEC document |
| November 04, 2014 Filed Nov 5, 2014 22:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 10,000 | $29.84 | $298,400.00 |
DisclosureSEC source: 0001209191-14-066728 · doc4.xml · nonDerivative · entry 4 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2014 Filed Nov 5, 2014 22:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $34.32 | $0.00 |
DisclosureSEC source: 0001209191-14-066728 · doc4.xml · derivative · entry 11 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2016-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| November 03, 2014 Filed Nov 5, 2014 22:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,684 | $112.80 | $302,755.20 |
DisclosureSEC source: 0001209191-14-066728 · doc4.xml · nonDerivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,210 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $112.80 (range $112.64 to $113.24). Read SEC document |
| November 03, 2014 Filed Nov 5, 2014 22:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 17,316 | $112.03 | $1,939,911.48 |
DisclosureSEC source: 0001209191-14-066728 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,894 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $112.03 (range $111.64 to $112.63). Read SEC document |
| November 03, 2014 Filed Nov 5, 2014 22:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 20,000 | $34.32 | $686,400.00 |
DisclosureSEC source: 0001209191-14-066728 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2014 Filed Jun 3, 2014 20:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $72.14 | $0.00 |
DisclosureSEC source: 0001209191-14-038670 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2024-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| March 21, 2014 Filed Mar 25, 2014 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 500 | $76.57 | $38,285.00 |
DisclosureSEC source: 0001209191-14-022943 · doc4.xml · nonDerivative · entry 4 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,210 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $76.57 (range $76.22 to $76.74). Read SEC document |
| March 21, 2014 Filed Mar 25, 2014 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,000 | $75.25 | $225,750.00 |
DisclosureSEC source: 0001209191-14-022943 · doc4.xml · nonDerivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,710 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $75.25 (range $75.00 to $75.85). Read SEC document |
| March 21, 2014 Filed Mar 25, 2014 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,750 | $74.47 | $204,792.50 |
DisclosureSEC source: 0001209191-14-022943 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,710 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $74.47 (range $73.99 to $74.96). Read SEC document |
| March 21, 2014 Filed Mar 25, 2014 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,450 | $73.53 | $180,148.50 |
DisclosureSEC source: 0001209191-14-022943 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,460 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $73.53 (range $72.99 to $73.98). F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 20, 2014 Filed Feb 24, 2014 21:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,200 | $84.13 | $269,216.00 |
DisclosureSEC source: 0001209191-14-013508 · doc4.xml · nonDerivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,910 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $84.13 (range $84.02 to $84.35). Read SEC document |
| February 20, 2014 Filed Feb 24, 2014 21:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,800 | $83.65 | $317,870.00 |
DisclosureSEC source: 0001209191-14-013508 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,110 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $83.65 (range $83.16 to $83.99). Read SEC document |
| February 20, 2014 Filed Feb 24, 2014 21:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,300 | $82.51 | $107,263.00 |
DisclosureSEC source: 0001209191-14-013508 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,910 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $82.51 (range $82.00 to $82.99). F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 22, 2014 Filed Jan 23, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $86.91 | $34,764.00 |
DisclosureSEC source: 0001209191-14-004558 · doc4.xml · nonDerivative · entry 4 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,210 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $86.91 (range $86.53 to $87.43). Read SEC document |
| January 22, 2014 Filed Jan 23, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,500 | $85.87 | $128,805.00 |
DisclosureSEC source: 0001209191-14-004558 · doc4.xml · nonDerivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,610 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $85.87 (range $85.50 to $86.47). Read SEC document |
| January 22, 2014 Filed Jan 23, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $84.90 | $50,940.00 |
DisclosureSEC source: 0001209191-14-004558 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,110 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $84.90 (range $84.47 to $85.45). Read SEC document |
| January 22, 2014 Filed Jan 23, 2014 21:16 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,800 | $83.89 | $486,562.00 |
DisclosureSEC source: 0001209191-14-004558 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,710 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $83.89 (range $83.46 to $84.37). F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| December 23, 2013 Filed Dec 26, 2013 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,200 | $73.45 | $88,140.00 |
DisclosureSEC source: 0001209191-13-058659 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,510 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $73.45 (range $73.33 to $73.63). Read SEC document |
| December 23, 2013 Filed Dec 26, 2013 21:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,100 | $72.95 | $517,945.00 |
DisclosureSEC source: 0001209191-13-058659 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,710 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $72.95 (range $72.33 to $73.30). F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2013 Filed Nov 21, 2013 21:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 200 | $67.15 | $13,430.00 |
DisclosureSEC source: 0001209191-13-053549 · doc4.xml · nonDerivative · entry 5 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,810 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $67.15 (range $67.14 to $67.16). Read SEC document |
| November 20, 2013 Filed Nov 21, 2013 21:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,700 | $66.25 | $112,625.00 |
DisclosureSEC source: 0001209191-13-053549 · doc4.xml · nonDerivative · entry 4 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,010 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $66.25 (range $66.00 to $66.80). Read SEC document |
| November 20, 2013 Filed Nov 21, 2013 21:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,900 | $65.35 | $320,215.00 |
DisclosureSEC source: 0001209191-13-053549 · doc4.xml · nonDerivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,710 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $65.35 (range $64.92 to $65.86). Read SEC document |
| November 20, 2013 Filed Nov 21, 2013 21:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 800 | $64.21 | $51,368.00 |
DisclosureSEC source: 0001209191-13-053549 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,610 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $64.21 (range $63.82 to $64.62). Read SEC document |
| November 20, 2013 Filed Nov 21, 2013 21:54 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $63.10 | $44,170.00 |
DisclosureSEC source: 0001209191-13-053549 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,410 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $63.10 (range $62.80 to $63.33). F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| October 24, 2013 Filed Oct 25, 2013 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,800 | $77.17 | $447,586.00 |
DisclosureSEC source: 0001209191-13-049384 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,110 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $77.17 (range $77.00 to $77.59). Read SEC document |
| October 24, 2013 Filed Oct 25, 2013 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,500 | $76.80 | $192,000.00 |
DisclosureSEC source: 0001209191-13-049384 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,910 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $76.80 (range $76.10 to $76.99). F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| September 25, 2013 Filed Sep 26, 2013 18:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,500 | $75.23 | $188,075.00 |
DisclosureSEC source: 0001209191-13-045743 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,410 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $75.23 (range $75.00 to $75.69). Read SEC document |
| September 25, 2013 Filed Sep 26, 2013 18:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,800 | $74.86 | $434,188.00 |
DisclosureSEC source: 0001209191-13-045743 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,910 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $74.86 (range $74.48 to $74.99). F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| August 29, 2013 Filed Sep 3, 2013 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $77.97 | $46,782.00 |
DisclosureSEC source: 0001209191-13-042692 · doc4.xml · nonDerivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,710 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $77.97 (range $77.86 to $78.07). Read SEC document |
| August 29, 2013 Filed Sep 3, 2013 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,010 | $77.29 | $464,512.90 |
DisclosureSEC source: 0001209191-13-042692 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,310 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $77.29 (range $76.83 to $77.79). Read SEC document |
| August 29, 2013 Filed Sep 3, 2013 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,690 | $76.55 | $129,369.50 |
DisclosureSEC source: 0001209191-13-042692 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,320 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $76.55 (range $75.83 to $76.82). F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| July 24, 2013 Filed Jul 26, 2013 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 600 | $87.03 | $52,218.00 |
DisclosureSEC source: 0001209191-13-038074 · doc4.xml · nonDerivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,010 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $87.03 (range $86.65 to $87.18). Read SEC document |
| July 24, 2013 Filed Jul 26, 2013 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,700 | $85.89 | $231,903.00 |
DisclosureSEC source: 0001209191-13-038074 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,610 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $85.89 (range $85.52 to $86.41). Read SEC document |
| July 24, 2013 Filed Jul 26, 2013 20:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,000 | $85.10 | $425,500.00 |
DisclosureSEC source: 0001209191-13-038074 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,310 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $85.10 (range $84.50 to $85.48). F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 21, 2013 Filed Jun 24, 2013 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,700 | $76.53 | $206,631.00 |
DisclosureSEC source: 0001209191-13-033384 · doc4.xml · nonDerivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,310 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $76.53 (range $76.28 to $76.77). Read SEC document |
| June 21, 2013 Filed Jun 24, 2013 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,500 | $75.85 | $341,325.00 |
DisclosureSEC source: 0001209191-13-033384 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,010 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $75.85 (range $75.29 to $76.23). Read SEC document |
| June 21, 2013 Filed Jun 24, 2013 20:40 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,100 | $74.81 | $82,291.00 |
DisclosureSEC source: 0001209191-13-033384 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,510 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $74.81(range $74.27 to $75.24). F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2013 Filed Jun 4, 2013 20:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $81.54 | $0.00 |
DisclosureSEC source: 0001209191-13-030497 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2023-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 22, 2013 Filed May 23, 2013 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,262 | $80.63 | $343,645.06 |
DisclosureSEC source: 0001209191-13-028457 · doc4.xml · nonDerivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,610 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $80.63 (range $80.01 to $81.00). Read SEC document |
| May 22, 2013 Filed May 23, 2013 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,538 | $79.50 | $122,271.00 |
DisclosureSEC source: 0001209191-13-028457 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,872 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $79.50 (range $79.00 to $79.98). Read SEC document |
| May 22, 2013 Filed May 23, 2013 20:14 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,500 | $78.48 | $196,200.00 |
DisclosureSEC source: 0001209191-13-028457 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,410 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $78.48 (range $77.94 to $78.82). F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 14, 2013 Filed May 16, 2013 20:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 60,000 | $81.15 | $4,869,000.00 |
DisclosureSEC source: 0001209191-13-026888 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,910 F1 · price: Open market sales reported on this line occurred at a weighted average price of $81.15 (range $80.81 to $81.41). F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| May 06, 2013 Filed May 8, 2013 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,000 | $77.41 | $541,870.00 |
DisclosureSEC source: 0001209191-13-024877 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,910 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $77.41 (range $77.01 to $77.71). Read SEC document |
| May 06, 2013 Filed May 8, 2013 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,300 | $76.19 | $99,047.00 |
DisclosureSEC source: 0001209191-13-024877 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,910 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $76.19 (range $75.90 to $76.74). F3 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2012 Filed Jun 1, 2012 21:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $59.55 | $0.00 |
DisclosureSEC source: 0001209191-12-031711 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2022-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| June 03, 2011 Filed Jun 6, 2011 19:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 7,500 | $55.02 | $412,650.00 |
DisclosureSEC source: 0001209191-11-033188 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,210 F1 · price: Open market sales reported on this line occurred at a weighted average price of $55.02 (range $55.00 to $55.09). F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| June 01, 2011 Filed Jun 2, 2011 20:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $53.85 | $0.00 |
DisclosureSEC source: 0001209191-11-032545 · doc4.xml · derivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2021-05-31 F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 27, 2011 Filed Jun 1, 2011 19:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option · Derivative | 7,500 | $0.00 Strike: $44.47 | $0.00 |
DisclosureSEC source: 0001209191-11-032238 · doc4.xml · derivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2011-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested. Read SEC document |
| May 27, 2011 Filed Jun 1, 2011 19:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 7,500 | $44.47 | $333,525.00 |
DisclosureSEC source: 0001209191-11-032238 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.